Q2 2022 EPS Estimates for Kura Oncology, Inc. (NASDAQ:KURA) Boosted by Jefferies Financial Group

Kura Oncology, Inc. (NASDAQ:KURAGet Rating) – Stock analysts at Jefferies Financial Group upped their Q2 2022 earnings per share estimates for Kura Oncology in a report released on Wednesday, May 4th. Jefferies Financial Group analyst R. Song now forecasts that the company will post earnings of ($0.50) per share for the quarter, up from their prior estimate of ($0.51). Jefferies Financial Group currently has a “Buy” rating and a $35.00 target price on the stock. Jefferies Financial Group also issued estimates for Kura Oncology’s Q3 2022 earnings at ($0.51) EPS, Q4 2022 earnings at ($0.51) EPS, FY2022 earnings at ($2.01) EPS, FY2023 earnings at ($1.97) EPS, FY2024 earnings at ($2.12) EPS, FY2025 earnings at ($1.98) EPS and FY2026 earnings at ($1.71) EPS.

Several other equities analysts have also recently commented on the company. Credit Suisse Group upped their price target on Kura Oncology from $25.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, February 25th. StockNews.com started coverage on Kura Oncology in a research report on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, SVB Leerink reduced their price objective on Kura Oncology from $41.00 to $28.00 and set an “outperform” rating for the company in a research report on Friday, February 25th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, Kura Oncology currently has an average rating of “Buy” and an average price target of $38.00.

Shares of KURA opened at $11.77 on Monday. The company has a 50-day simple moving average of $15.72 and a 200-day simple moving average of $15.01. Kura Oncology has a 52 week low of $11.49 and a 52 week high of $26.41. The firm has a market capitalization of $784.31 million, a P/E ratio of -5.91 and a beta of 1.39.

Kura Oncology (NASDAQ:KURAGet Rating) last announced its earnings results on Wednesday, May 4th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.03. During the same quarter in the prior year, the company posted ($0.46) earnings per share.

Several institutional investors and hedge funds have recently modified their holdings of KURA. Marshall Wace LLP acquired a new position in shares of Kura Oncology in the 1st quarter worth approximately $372,000. Morgan Stanley raised its holdings in shares of Kura Oncology by 973.9% in the 2nd quarter. Morgan Stanley now owns 181,511 shares of the company’s stock worth $3,785,000 after buying an additional 164,609 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Kura Oncology by 33.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 50,731 shares of the company’s stock worth $949,000 after buying an additional 12,788 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Kura Oncology by 0.8% in the 3rd quarter. BlackRock Inc. now owns 5,001,416 shares of the company’s stock worth $93,678,000 after buying an additional 39,035 shares in the last quarter. Finally, Barclays PLC increased its holdings in Kura Oncology by 11.0% during the 3rd quarter. Barclays PLC now owns 82,935 shares of the company’s stock valued at $1,553,000 after purchasing an additional 8,189 shares in the last quarter. 94.65% of the stock is owned by institutional investors and hedge funds.

Kura Oncology Company Profile (Get Rating)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.

Read More

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.